# Jianjun Zhang

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/jianjun-zhang-2/

## Facts

| Field | Value |
| --- | --- |
| Citations | 21,537 |
| Field | Lung Cancer Treatments and Mutations |
| h-index | 67 |
| i10-index | 225 |
| Last Known Institution | The University of Texas MD Anderson Cancer Center |
| OpenAlex ID | https://openalex.org/A5100358178 |
| ORCID iD | 0000-0001-7872-3477 |
| Works | 1,040 |

## Researcher papers

Showing 12 of 17.

- [<i>STK11/LKB1</i> Mutations and PD-1 Inhibitor Resistance in <i>KRAS</i>-Mutant Lung Adenocarcinoma](https://scholariq.org/papers/i-stk11-lkb1-i-mutations-and-pd-1-inhibitor-resistance-in-i-kras-i-mutant-lung/)
- [Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non–Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study](https://scholariq.org/papers/local-consolidative-therapy-vs-maintenance-therapy-or-observation-for-patients/)
- [Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study](https://scholariq.org/papers/local-consolidative-therapy-versus-maintenance-therapy-or-observation-for/)
- [Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing](https://scholariq.org/papers/intratumor-heterogeneity-in-localized-lung-adenocarcinomas-delineated-by/)
- [Co-occurring Genomic Alterations Define Major Subsets of <i>KRAS</i> -Mutant Lung Adenocarcinoma with Distinct Biology, Immune Profiles, and Therapeutic Vulnerabilities](https://scholariq.org/papers/co-occurring-genomic-alterations-define-major-subsets-of-i-kras-i-mutant-lung/)
- [Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial](https://scholariq.org/papers/neoadjuvant-nivolumab-or-nivolumab-plus-ipilimumab-in-operable-non-small-cell/)
- [Structure-based classification predicts drug response in EGFR-mutant NSCLC](https://scholariq.org/papers/structure-based-classification-predicts-drug-response-in-egfr-mutant-nsclc/)
- [Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in <i>EGFR</i> -Mutant NSCLC](https://scholariq.org/papers/landscape-of-egfr-dependent-and-independent-resistance-mechanisms-to-osimertinib/)
- [Diminished Efficacy of Programmed Death-(Ligand)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma Is Affected by KRAS Mutation Status](https://scholariq.org/papers/diminished-efficacy-of-programmed-death-ligand-1-inhibition-in-stk11-and-keap1/)
- [Single-cell analyses reveal increased intratumoral heterogeneity after the onset of therapy resistance in small-cell lung cancer](https://scholariq.org/papers/single-cell-analyses-reveal-increased-intratumoral-heterogeneity-after-the-onset/)
- [Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer](https://scholariq.org/papers/oncogene-specific-differences-in-tumor-mutational-burden-pd-l1-expression-and/)
- [Genomic Landscape and Immune Microenvironment Features of Preinvasive and Early Invasive Lung Adenocarcinoma](https://scholariq.org/papers/genomic-landscape-and-immune-microenvironment-features-of-preinvasive-and-early/)

## Researcher topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Colorectal Cancer Treatments and Studies](https://scholariq.org/topics/colorectal-cancer-treatments-and-studies/)

## Researcher university

- [The University of Texas MD Anderson Cancer Center](https://scholariq.org/institutions/the-university-of-texas-md-anderson-cancer-center/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.